GlassScriptPhysician profile
Suzanne C Nash
NPI 1336146273
$14,848.00
in general payments reported to CMS, 2019-2025
81 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,992 · 2020: $1,975 · 2021: $2,203 · 2022: $2,261 · 2023: $2,358 · 2024: $1,981 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,237 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,237.46 |
| Education | $179.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,362.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,471.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,116.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,110.56 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $867.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $669.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $619.25 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $604.96 | 2019-2025 | |
| Abbott Laboratories | $514.67 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Amgen INC. | $378.82 | 2019-2025 | Evenity, Prolia, Otezla |
| Grifols USA, LLC | $283.38 | 2019-2023 | Prolastin-C Liquid |
| Allergan, INC. | $283.12 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $274.81 | 2019-2025 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $256.87 | 2019-2025 | M-M-R II, Vaxneuvance, Capvaxive |
| Sanofi-Aventis U.S. LLC | $254.04 | 2019-2025 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.